Company Overview
BioCardia, Inc. operates as a clinical-stage regenerative medicine company focused on the United States market, where it develops cellular and cell-derived therapeutics specifically designed to treat cardiovascular and pulmonary diseases. The company functions within the broader healthcare sector and the specialized biotechnology industry, positions that define its operational scope and regulatory environment. In terms of scale, BioCardia holds a market capitalization of $12.31M and reports annual revenue figures that are not available in the current dataset, while specific employee headcount data is also not listed. The current market cap of $12.31M indicates that the company maintains a relatively small valuation relative to large-cap pharmaceutical peers, reflecting its status as an early-stage entity where revenue generation is still being established through clinical development rather than commercial sales.
Financial Health
The company's financial statements for the trailing twelve months show a net income of $-8,228,000 and an EBITDA of $-8,254,000, while revenue data is not available for calculation. The significant gap between the reported net income and EBITDA reveals a cost structure heavily influenced by non-operating expenses or interest costs that impact the bottom line, given that EBITDA and net income are nearly identical figures. Free cash flow stands at $-4,657,750, which indicates that the company is consuming cash to fund its operations and clinical trials rather than generating surplus liquidity for distribution to shareholders or debt repayment. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability on a gross or operational level, a common characteristic of clinical-stage biotechnology firms focused on product development. The balance sheet shows a cash position of $2.50M against total debt of $528,000, resulting in a debt-to-equity ratio of 58.99, which suggests the company relies primarily on equity financing rather than leverage to fund its activities. The current ratio is 1.12, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the margin above the 1.0 threshold is narrow. Return on equity is reported at -950.1% and return on assets at -145.0%, metrics that reveal the company is currently incurring losses relative to its capital base and asset holdings, reflecting the high-burn nature of developing advanced cell therapies.
Valuation Assessment
Valuation multiples for BioCardia, Inc. include a trailing P/E ratio that is not available due to negative earnings and a forward P/E of -2.07, implying that the market is pricing the stock based on expected future earnings that remain below zero. The price-to-book ratio is 13.98, which indicates that the market is valuing the company at a significant premium over its net book value, likely due to the high intrinsic value of its intellectual property and pipeline assets that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and the EV/EBITDA of -1.30, further suggest that traditional multiple-based comparisons with profitable peers are not applicable. The stock's trading range over the past year spans from a 52-week low of $1.00 to a high of $3.20, providing a clear context for current valuation relative to recent price extremes. The beta value of 0.55 indicates that the stock's price volatility is lower than that of the broader market, suggesting a more stable price trajectory despite the inherent risks associated with biotechnology development.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of earnings growth rates against revenue growth rates in the current reporting period. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, instead choosing to reinvest all available capital and earnings into research and development activities to advance its clinical pipeline. The absence of a dividend yield and the negative earnings profile confirm that the company is prioritizing growth through clinical progression rather than providing current income to shareholders. The overall growth and income profile is characterized by a reliance on future clinical trial success rather than current cash flow generation or dividend distributions.